Ligand Pharmaceuticals (LGND) Long-Term Investments (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Long-Term Investments data on file, last reported at $87.8 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 704.64% year-over-year to $87.8 million; the trailing twelve-month figure through Mar 2026 stood at $87.8 million (up 704.64% YoY), and the FY2025 full-year result was $46.5 million, changed N/A from the prior year.
• Long-Term Investments climbed to $87.8 million in Q1 2026, from $46.5 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $375.0 million in Q1 2022 to a low of $3.0 million in Q4 2022.
• A 5-year average of $134.3 million and a median of $34.8 million in 2023 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments plunged 99.2% in 2022 and surged 704.64% in 2026, its largest moves.
• Tracing LGND's Long-Term Investments over 5 years: stood at $3.0 million in 2022, then surged by 319.83% to $12.6 million in 2023, then decreased by 13.39% to $10.9 million in 2024, then soared by 326.29% to $46.5 million in 2025, then soared by 88.75% to $87.8 million in 2026.
• Business Quant data shows LGND's Long-Term Investments at $87.8 million in Q1 2026, $46.5 million in Q4 2025, and $9.4 million in Q3 2025.